TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05728528
Drug: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Study: NCT06789549
Drug: oxymetazoline nasal drops
Normalized name: oxymetazoline Nasal Solution
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
Study: NCT06793228
Drug: Nanocrystalline Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
Study: NCT06793228
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)
Study: NCT06793228
Drug: PTOC
Normalized name: Optochin
DrugBank: Mercaptocarboxylate Inhibitor (DB02706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
Study: NCT04634877
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT04634877
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04634877
Drug: Placebo for pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04634877
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
Study: NCT04634877
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Study: NCT04634877
Drug: Cisplatin (as radiosensitizer)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Study: NCT05689229
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Study: NCT05785624
Drug: Vixarelimab
Normalized name: Vixarelimab
DrugBank: Vixarelimab (DB16350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.
Study: NCT04847544
Drug: ADX-629
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX-629 administered orally twice daily (BID) for up to 28 days.
Study: NCT06237426
Drug: Methylone
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A course of treatment includes 4 weekly doses of TSND-201.
Study: NCT05121740
Drug: Plitidepsin 1.5 mg / day
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
Study: NCT05121740
Drug: Plitidepsin 2.0 mg / day
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
Study: NCT05121740
Drug: Plitidepsin 2.5 mg / day
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
Study: NCT06796803
Drug: camrelizumab combined with rivoceranib and HAIC
Normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: systemic therapy combined with locoregional theraphy as conversion therapy
Study: NCT06796803
Drug: camerlizumab + rivoceranib
Normalized name: Lambrolizumab
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: systemic therapy
Study: NCT06643832
Drug: Lidocaine (drug)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine will be used by mixing it with the propofol before intravenous injection
Study: NCT04704661
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06291376
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
Study: NCT06471686
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 pills three times a day
Study: NCT04716634
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
Study: NCT04716634
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
Study: NCT06789913
Drug: RLY-2608
Normalized name: RLY-2608
DrugBank: RLY-2608 (DB16751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
Study: NCT06793670
Drug: Landiolol
Normalized name: Landiolol
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intravenous infusion of landiolol
Study: NCT06793371
Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CK-4021586 administered orally
Study: NCT05053321
Drug: Valbenazine
Normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be treated with Valbenazine for 6 weeks.
Study: NCT06628362
Drug: CT-388
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Study: NCT06276556
Drug: ABP-671
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.
Study: NCT06276556
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
Study: NCT05384015
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance).
Study: NCT05384015
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion
Study: NCT05384015
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles
Study: NCT05384015
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles
Study: NCT06125587
Drug: Chiglitazar
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
Study: NCT06125587
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Study: NCT05048134
Drug: HRS2300、trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HRS2300 combined with trametinib
Study: NCT05048134
Drug: HRS2300、Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS2300 combined with Almonertinib
Study: NCT05640830
Drug: trastuzumab, bevacizumab with paclitaxel (triple combination)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
Study: NCT06074510
Drug: Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Normalized name: Piflufolastat F 18 Intravenous Solution [PYLARIFY]
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
Study: NCT06466122
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06466122
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06363994
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
Study: NCT06363994
Drug: Bendamustine Injection
Normalized name: bendamustine Injection
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive Bendamustine by injection as per the protocol
Study: NCT06363994
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible patients will receive Rituximab by injection as per the protocol
Study: NCT06363994
Drug: Orelabrutinib Placebo
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
Study: NCT06157892
Drug: disitamab vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenous)
Study: NCT06157892
Drug: tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg given twice daily by mouth (orally)
Study: NCT04730609
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
Study: NCT06284343
Drug: Anticoagulant
Normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
Study: NCT05083923
Drug: Diroximel fumarate
Normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06108414
Drug: low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Study: NCT06352866
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a disorder of the lymphatic system
Study: NCT06352866
Drug: Teclistamab(FDA-approved)
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab is a FDA-approved drug for the treatment of advanced MM after 4 lines of therapy.
Study: NCT06108414
Drug: Standard-dose rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Study: NCT04397003
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Supplied by AstraZeneca
Study: NCT03454750
Drug: 177Lu-PSMA
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
Study: NCT04749628
Drug: cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex (cannabidiol) oral solution
Study: NCT06340347
Drug: Osivelotor
Normalized name: Osivelotor
DrugBank: Osivelotor (DB18071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367
Study: NCT05473195
Drug: Ethionamide 250mg
Normalized name: ETHIONAMIDE 250MG TAB
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide 250 mg po OD (Eto250)
Study: NCT05473195
Drug: Ethionamide 250 mg
Normalized name: ethionamide 250 MG
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide 750 mg po given in a single or divided dose (Eto750)
Study: NCT05473195
Drug: Isoniazid 300 MG
Normalized name: isoniazid 300 MG
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid 300 mg po OD (INH)
Study: NCT04822337
Drug: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
Study: NCT04637763
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for lymphodepletion
Study: NCT04929249
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Study: NCT05471479
Drug: Activated Charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal
Study: NCT04817254
Drug: TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 on days 1-5 of cycles 1-6
Study: NCT04817254
Drug: ipilimumab 3mg/kg
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg q 4 weeks for cycles 1-4
Study: NCT04817254
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
Study: NCT04817254
Drug: ipilimumab 1mg/kg
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/kg q 4 weeks for cycles 1-4
Study: NCT05824832
Drug: Interscalene block with the addition of buprenorphine, clonidine, dexamethasone
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
Study: NCT05824832
Drug: Interscalene block with buprenorphine alone
Normalized name: Ivy Block
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
Study: NCT05900050
Drug: VS-01 on top of SOC
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
Study: NCT05153915
Drug: Tacrolimus granules
Normalized name: tacrolimus Granules for Oral Suspension
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06346288
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
Study: NCT05180162
Drug: 68Ga-FAP-2286
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)
Study: NCT05252754
Drug: Tacrolimus capsule
Normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
Study: NCT05342636
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg administered via oral capsules each day
Study: NCT05342636
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.
Study: NCT05342636
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
Study: NCT05940402
Drug: Emraclidine
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05610774
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
Study: NCT05610774
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
Study: NCT05888493
Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
Study: NCT05888493
Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5